Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method

Journal of Clinical Microbiology

Volumn 52, Issue 9, 2014, Pages 3399-3401

  Ross, James E ^a   Mendes, Rodrigo E ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; TELAVANCIN;

DRUG EFFECTS; ENTEROCOCCUS FAECALIS; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES; QUALITY CONTROL; STANDARDS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECALIS; HUMANS; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84906100555     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01210-14     Document Type: Article

References (12)

1. Theravance Inc. 2014. Vibativ package insert. Theravance, Inc., San Francisco, CA. http://www.vibativ.com.
2. Putnam SD, Sader HS, Moet GJ, Mendes RE, Jones RN. 2010. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn. Microbiol. Infect. Dis. 67:359-368. http://dx.doi.org/10.1016/j.diagmicrobio.2010.03.009.
3. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2012. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob. Agents Chemother. 56:3999-4004. http://dx.doi.org/10.1128/AAC.00011-12.
4. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR, Jr, Moeck G. 2008. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob. Agents Chemother. 52:1597-1603. http://dx.doi.org/10.1128/AAC.01513-07. (Pubitemid 351614648)
7. Arhin FF, Tomfohrde K, Draghi DC, Aranza M, Parr TR, Jr, Sahm DF, Moeck G. 2008. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters. Diagn. Microbiol. Infect. Dis. 62:92-95. http://dx.doi.org/10.1016/j.diagmicrobio.2008. 05.009.
8. Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB, Goldstein BP. 2007. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J. Clin. Microbiol. 45:3151-3154. http://dx.doi.org/10.1128/JCM.02411-06. (Pubitemid 47585633)
9. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters, 3rd ed. CLSI M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Reference deleted.
12. Turnidge J, Bordash G. 2007. Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing. Antimicrob. Agents Chemother. 51: 2483-2488. http://dx.doi.org/10.1128/AAC.01457-06. (Pubitemid 47047327)